Le Goaster J, Houyez F, Frances C, Pessac B, Courpotin C, Lasfargues G, Dormont D; International Conference on AIDS.
Int Conf AIDS. 1992 Jul 19-24; 8: 99 (abstract no. PuB 7301).
Hop. Trousseau, Paris.
OBJECTIVE: Phase 1 evaluation of the safety and efficacy of orally administrated derived pyran molecule in a small group of HIV infected patients. RATIONALE: Following our evaluation of early neuro-hormonal disorders of ACTH/B Endorphins and ACTH/Cortisol total ratios related to the HIV infection, we speculated an early viral impact on the neuroimmunological modulation through the Pro-Opio-Melano-Cortine (P.O.M.C.) gene and we choose to screen a pyran molecule reported to be able to interfere with the regulation of the P.O.M.C. gene expression. METHODS AND RESULTS: Therefore 10 patients were treated with the derived pyran molecule, 40 mg/daily x 3 weeks and 40 mg/daily x 3 days/week during 9 months, no clinical renal and hepatic toxicity were documented, no biological toxicity was identifiable. Antigenemia remained negative, B2 microglobulinemia stable, T4 count stable-T4/T8 stable. The pyran appeared well tolerated. In the 10 cases the evolution was positive for 7 patients who remained free of any infections, a clear enhancement of T4 count and T4/T8 ratio was observed in 1 patient. CONCLUSION: After 9 months, we evidenced the lack of both clinical and biological toxicity of pyran treatment on HIV-infected individuals after verification and control of the classical parameters of the HIV disease evolution. Pyran seems to have a positive impact on the T cells count in the patients. Pyran treatment has to be evaluated in a large double-bind clinical trial.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adrenocorticotropic Hormone
- HIV Infections
- HIV Seropositivity
- Humans
- Hydrocortisone
- T-Lymphocytes
- Thyroxine
Other ID:
UI: 102202300
From Meeting Abstracts